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Antibodies against Extractable Nuclear Antigens, Anthony A. M. Ermens, 1 * Angelique J. M. Bayens, 1 Anita C. M. van Gemert, 1 and Johannes L. P. van Duijnhoven 2 ( 1 Diaconessenhuis, Eindhoven and 2 Elkerliek Hospital, Helmond, The Netherlands; *address for correspondence: Clin. Lab., Diaconessenhuis, P.O. Box 90052, 5600 PD, Eindhoven, The Netherlands; fax 31-402335595) Detection of antinuclear antibodies (ANA), usually by indirect immunofluorescence, is generally regarded as an important test in the diagnosis of systemic autoimmune diseases. If ANA are present, the subsequent identification of autoantibody specificity contributes to the final diagnosis and may also be helpful in disease management. ANA, which show many different serologic specificities, are partly directed against extractable nuclear antigens (ENA). The most common ENAs are SSA, SSB, Sm, RNP, and Scl-70. The presence of these specific ENA antibodies is related to certain autoimmune diseases such as Sjö gren syndrome (SSA, SSB), mixed connective tissue disease (RNP), systemic lupus erythematosus (Sm), and scleroderma (Scl-70) [1] .
ENA antibodies can be detected in several ways. Double immunodiffusion, often in combination with immunoblotting (IB), is widely used but is time-consuming and requires well-trained and experienced technicians [2] . A few years ago several ELISAs were introduced which have proven to be both sensitive and specific for detection of ENA antibodies [2] [3] [4] . However, they are expensive and require the availability of an ELISA reader. Recently, a simple dot-blot method (DB) for the detection of ENA antibodies [Biomedical Diagnostics (BMD)] has become available. In the present study we compared this DB with the currently used combination of counterimmunoelectrophoresis and immunoblotting (CIE/IB) for the detection of antibodies against ENA.
Sera from 146 patients were selected for the evaluation of detection of antibodies directed against SSA, SSB, Sm, and RNP. Besides samples with CIE/IB-proven ENA antibodies, samples with negative results were included to check for cross-reactivity and purity of the antigens used in the DB method. Moreover, 35 samples from patients suspected for scleroderma or a related disease were selected for Scl-70 antibody detection. All patient sera used contained ANA as confirmed by indirect immunofluorescence and were selected from a large sample collection to ensure a variety of antibodies. The sera in this collection, some of which were sent from other laboratories, were stored at Ϫ70°C until analysis.
CIE for the detection of antibodies against SSA, SSB, RNP, and Sm was performed as described by Bunn and Kveder [5] . Briefly, 10 L of patient serum or characterized antiserum was loaded into 3-mm wells cut out of an agarose plate. Subsequently, antigen was put in 2-mmwide troughs at the cathodal site of the wells. After electrophoresis the plates were washed with cold PBS and stained with Coomassie Blue. Antibodies present in patient samples could be detected and identified by the formation of specific precipitation lines between wells filled with patient samples and wells filled with characterized antisera. The antigen sources used were rabbit thymus (for detection of antibodies against SSB, Sm, and RNP) and bovine spleen (for detection of SSA antibodies).
If the results of CIE were doubtful or weak an IB was performed as described by Verheijen et al. [6] . Detection of antibodies against Scl-70 was done only by IB. Briefly, protein extracts from HeLa cells were separated on a polyacrylamide gel and transferred to nitrocellulose. Strips of this blot were incubated with patient sera. Antibody-antigen complexes were stained with 4-chloro-1-naphthol in the horseradish peroxidase system. The subsequent identification of antibodies was based on the specific immunoblot pattern.
The DB method of BMD is a qualitative assay, which utilizes strips of nitrocellulose on which purified antigens are blotted at prelocated spots (see Fig. 1 ). The antigen sources used are bovine and rabbit thymus (SSA, Sm, and Scl-70) or calf spleen and rabbit thymus (SSB and Sm/ RNP). The test procedure was performed according to directions supplied by the manufacturer. Test strips were incubated for 10 min with a 50-fold dilution of patient serum in a PBS-Tween solution supplied by the manufacturer. Subsequently the test strips were washed by gentle agitation in a test tube filled with PBS-Tween for 1 min. After the excess buffer solution was removed with a filter paper, the test strips were incubated with an alkaline phosphatase-Protein A conjugate for 10 min. The test strips were then washed for 1 min by gentle agitation in a test tube filled with PBS-Tween. Again excess buffer was removed with a filter paper. Finally the test strips were stained with 5-bromo-4-chloro-3-indolylphosphate/nitroblue tetrazolium for 5 min. The reaction was terminated by washing the test strips with deionized water. The strips were then air-dried. Only strips on which the positive control position was stained as a clearly marked blue spot were able to be evaluated and used for this study. The absence of the blue spot on the positive control position occurred only once during the study.
The comparison between CIE/IB and DB for the individual ENA antibodies is presented in Table 1 . The agreement between CIE/IB and DB was 99%, 100%, 100%, 99%, and 97% for SSA, SSB, RNP, Sm, and Scl-70, respectively. The samples that showed a discrepancy for SSA and Sm proved to be only weakly demonstrable in the test method with the positive result. The corresponding patients were diagnosed with a systemic autoimmune disease or were seriously suspected of having one because of their clinical performance. The medical file of the patient with the CIE/IB-positive Scl-70 did not reveal specific symptoms for scleroderma.
The sensitivity and specificity of the DB was calculated by comparison with the CIE/IB and also are presented in Table 1 . Overall the sensitivity and specificity of DB for detection of specific ENA antibodies were excellent with the exception of sensitivity for Scl-70 and Sm, which was reasonable. However, as no gold standard for ANA characterization exists, one has to be careful with the interpretation of these data. The same accounts for the five test results that showed a discrepancy. These might be the result of nonspecific binding but might also indicate a (weak) ENA antibody. With the exception of the sample that was positive for Scl-70 by CIE/IB only, this would concur with the suspected or diagnosed presence of an autoimmune disease in these particular patients.
The DB test is advantageous for time management as described previously for a similar test system for ENA antibodies [7] . A single test required ϳ30 min. The test procedure could easily be performed in batch assays as every 5 min a new DB test could be started. Visual scoring of the test-strip reactions was mastered quickly after a few assays. After a short training period, technicians were able to perform the entire test procedure. Moreover, in comparison with CIE/IB the time required to report results was substantially shortened from days to hours.
A major drawback of the DB method is the blotting of RNP antigen in combination with Sm antigen (see Fig. 1 ). This implies that if both the Sm spot and the Sm/RNP spot are positive the presence of Sm antibodies alone cannot be distinguished from the combined presence of Sm and RNP antibodies. For all nine samples that, according to DB, contained Sm antibodies both spots were positive. As this only indicates the possible presence of RNP antibodies these results could not be included in the study. Several ELISAs for ENA characterization are now also available for routine use [2] [3] [4] . Compared with the DB, the high costs of these systems render them less attractive although they exhibit excellent sensitivities and specificities and also are less time-consuming than CIE/ IB.
We conclude that DB may be an attractive method for those laboratories that wish to perform ENA antibody characterization without substantial investments in equipment and (or) the training of laboratory staff. Huntington disease (HD) is an autosomal dominant progressive neurodegenerative disorder characterized by motor disturbance, cognitive loss, and psychiatric manifestations. Mapping of the putative HD gene to chromosome 4 in 1983 [1] facilitated presymptomatic testing of people at risk for HD by using linked polymorphic DNA markers. This method required DNA from related individuals to track the putative HD allele within a family. The situation changed after the gene responsible for HD was identified in 1993 [2] , and a new method, based on PCR, became available for the detection of the disorder. This new method also enabled direct mutation analysis and genetic counseling for new mutation HD families. The mutation mechanism was found to be the expansion of a CAG repeat in the 5Ј-translated region of the HD gene. The mechanism by which the increased trinucleotide repeat length leads to the characteristic clinical symptoms and neuropathology of HD is, as yet, unknown. The CAG repeat of the HD gene is polymorphic in the population, varying between 8 and 36 repeats on normal chromosomes and is expanded with Ͼ37 repeats in chromosomes of HD-affected individuals [3] .
Since the first description of a PCR method to detect the mutation in the HD gene was published, there have been difficulties reproducing these results [2] . The difficulties in the PCR are caused by the composition of the DNA sequence 3Ј to the CAG repeat, which has a high GC content and is also highly repetitive. The other difficulty with the initial method was that it utilized primers flanking a region of a polymorphic CCG repeat as well as the CAG repeat at the 5Ј end of the gene. This leads to a PCR test being developed that is easy to use and that does not amplify the CCG region [4] . This detection of the number of CAG repeats allows the direct presymptomatic diagnosis of the disease.
Although this modified method is more accurate and produces cleaner gel bands than can be obtained by the first primer set, the measurement of the length of the trinucleotide repeat remains very difficult. The repeat length detection requires radioactive analysis or silver staining of polyacrylamide gels, which produces several shadow bands around the main allele band due to the nature of the repeat amplifications. In addition, it is often very difficult to distinguish between the main and shadow bands when they have similar intensities. Although allele sizes can be determined by using appropriate size markers and controls with known numbers of CAG repeats, it is difficult to size the alleles for two reasons. First, if the product yield is low, it produces a very faint signal, and second, as the migration rate across the gel is different in different lanes, the calibrator size values may be rendered inaccurate.
Because the CAG repeat can expand over 60 units or even more, the intensity of larger HD alleles can be extremely weak and therefore cannot be detected by conventional methods. In these cases the amount of PCR products cannot be increased by increasing the number of PCR cycles, as this causes high background [5] and confuses the detection of the products on the gel. Therefore conventional PCR and the usual detection of products are generally not suitable for appropriate presymptomatic diagnosis of individuals at risk for HD. Particular difficulties occur when the number of CAG repeats are in the range of 35 to 38. This requires a very exact measurement for predicting the risk of the individual or when a weak PCR signal is obtained from an expanded allele.
We report a suitable method to solve these problems by amplifying alleles from the CAG region of the HD gene by fluorescent PCR.
The fluorescent PCR method [6] has particular advantages in the detection of HD alleles compared with the conventional method: It is more sensitive, it can be used for quantitative measurement of bands, and fewer PCR cycles are required for the same level of detection, resulting in cleaner band pictures and easier interpretation. Further advantages are that signals can be easily visualized even if very weak, allowing the detection of alleles with high numbers of CAG repeats, and that highly accurate molecular mass determination is possible because of the inclusion of internal size calibrators.
We report our fluorescent PCR-based method for accurate detection of CAG numbers from the 5Ј region of the HD gene. Our previously described PCR conditions [7, 8] for the detection of CAG repeats have been modified to
